

This English version of the Expert Committee Decision is intended to be reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The Food Safety Commission of Japan (FSCJ) shall not be responsible for any consequence resulting from use of this English version.

Guidance on the Use of the BMD Approach in Risk Assessment by FSCJ

[For toxicological data from experimental animal studies]

I. Purpose

This guidance provides our basic stance and procedures for the use of the benchmark dose (BMD) approach for deriving a suitable point of departure (POD) in the risk assessment of chemicals in food with the aim to ensure greater consistency and transparency when the FSCJ applies the BMD approach in the risk assessment.

II. Definition

The definitions of terms in this guidance are as follows:

1. **Benchmark Response (BMR)**

BMR is a change in the response level relative to the background response calculated from a fitted dose-response curve obtained by fitting a mathematical function (a mathematical model) to the overall dose-response relationship (i.e. the relationship between the level of exposure to a chemical and the frequency or magnitude of the effect caused by the given chemical).

2. **Benchmark Dose (BMD)**

An exposure level of a chemical (i.e. a dose of chemical) corresponding to a predetermined BMR.

3. **Benchmark Dose Approach (BMD approach)**

The approach derives a BMD and its confidence interval assuming that a specific mathematical function describes the dose-response relationship.

4. **Benchmark Dose Lower Confidence Limit (BMDL)**

The lower confidence limit of the BMD.

Generally, the lower limit/bound of a two-sided 90% confidence interval or a one-sided 95% lower confidence interval on the BMD

5. AIC (Akaike Information Criterion)

A Criterion for comparing the balance between model complexity and goodness-of-fit among different models

$$AIC = -2 \log(L) + 2k$$

$\log(L)$: maximum log-likelihood of the model given the data

k: number of estimated parameters included in the model

The model providing a good fit with a few parameters has a relatively low AIC value, and is considered preferable.

6. Dichotomous data

Quantal data, a type of categorical data, where an effect observed from exposure to a chemical in individuals, is classified into one of two possible outcomes, e.g. dead or alive, with or without tumor.

7. Ordinal categorical data

A type of categorical data where an effect observed such as from exposure to a chemical in individuals to be allocated to several possible categories, where differences at different points of the scale are not necessarily equivalent, e.g. test results for urinary glucose level (-, ±, +, ++) and data for cancer stage.

8. Continuous data

A type of data where effects observed such as from exposure to chemical measured on a continuum such as organ weight or enzyme concentration.

9. Restriction

Restriction is required to limit the range of parameter(s) in the parameter estimation process. Restriction in the BMD approach limits range of parameters included in the mathematical model so that the shape of the dose-response curve derived from the mathematical model would be biologically plausible.

III. Use of the BMD Approach in FSCJ's Risk assessment

This guidance provides basic guidance for the use of the BMD approach in the hazard characterization of chemicals to calculate the BMD and its confidence intervals.

Expert judgment on biological significance as well as statistical analyses for calculating BMD and its confidence interval is required. In the case of adopting a concept or method not in line with this guideline, the details and reason shall be reported.

1. Collection and selection of dose-response data allowing the application of the BMD approach

- (1) Collect all the available dose-response data such as observed data on specific doses and their corresponding responses for the chemical to be evaluated (hereinafter referred to as “relevant substance”).

Depending on types and amount of data available, endpoints may be selected following the selection of toxicity studies for BMD analysis or the studies may be selected following the selection of endpoints under expert judgment.

- (2) For the dataset selected using the procedures indicated in (1) above that is sufficient to establish a dose-response relationship, seek whether the following conditions apply in collaboration with experts.
 - A) The study design employed such as the selection of target animal species, number of animals, route(s) of administration, and dosage are appropriate.
 - B) The observed endpoint(s) has toxicological significance
Human extrapolation should also be considered.
 - C) Datasets examined for the feasibility of BMD analysis should include the following information.
 - a. Dichotomous data: the number of animals per dose group and number of animals showing response.
 - b. Ordinal categorical data: number of animals per dose group, number of animals showing response and degree of response in each individual (grades)
 - c. Continuous data: data per each individual
When individual data are unavailable, number of animals, central estimate (mean or median value) and a measure of response variability (standard deviation (SD) or interquartile range) for each dose group

It should be noted that when dataset is expected to include covariates (i.e. any variable that affects the outcome such as litter size in developmental toxicity study), the relevant information should be provided.

- (3) To increase the number of samples to be analyzed and to increase confidence in the BMD analysis, datasets that are statistically and biologically compatible may be combined based on expert judgement, and be analyzed as a dataset with reduced sampling bias. Statistical and

biological judgement should be justified prior to combining the datasets to generate a reliable dose-response relationship. Characteristics of each study design including individual datasets affecting the dose-response pattern such as dose range, species, sample size, and data measurement method shall be explored. When available, it is recommended to use the original data (i.e. individual data) to construct the combined dataset since the original data would provide detailed information on the response in the dose region corresponding to the BMR.

(4) Careful consideration is needed when reducing (dichotomizing) the ordinal categorical data, data in which histopathological observations in treatment groups are reported by severity category (i.e. grade), to quantal data. Toxicological significance of the effects should be determined based on expert judgement taking into account types of histopathological observations, approach to categorizing the severity and incidence of observed effects. The incidence of observed effects in the control groups should also be examined. Consider the incidence of histopathological observations equal to or severer than the grade to be adverse, and treat the total incidence as quantal data.

2. Selection of BMR

(1) Dichotomous (Quantal) data

A) Calculations of BMD and its confidence interval (BMD calculation) require the selection of a BMR.

Considering the statistical power of data from experimental animal studies, comparing potencies across chemicals or endpoints and consistent¹ relationship between the BMD and the traditional NOAEL approach, an extra risk² of 10% selected for BMR is generally used for BMD calculation.

B) However, a BMR of 10% extra risk is not always suitable for all dose-response datasets. The BMR shall be selected considering the biological significance and the characteristics of the dataset to be used for modeling under expert judgement.

C) For example, when 10% extra risk (i.e. the response level) is much smaller than the response observed at the lowest dose, and the BMD calculation involves downward

¹S. Sand *et al.*, A Signal-to-Noise Crossover Dose as the Point of Departure for Health Risk Assessment. Environmental Health Perspective. 2011, 119: 1766-1774.

²Extra risk: A measure of risk proportional to an increase in the risk of an effect adjusted for the background incidence of the same effect. An absolute change in frequency of response (additional risk, calculated as $P(d) - P(0)$) divided by the non-affected fraction in the controls.

Extra risk is calculated as follows: $[P(d) - P(0)] / [1 - P(0)]$.

$P(d)$: The probability of response at a dose

$P(0)$: The probability of response in the absence of exposure (i.e. background response in controls)

extrapolation to range much below the lowest dose, it may be desirable to use a BMR greater than 10% extra risk.

In a case where dose-response data relating to effects on F1 offspring from reproductive and developmental toxicity studies are used, it may be recommended to apply a BMR lower than 10% extra risk from a statistical standpoint.

(2) Continuous Data

- A) When there is a scientific basis to establish a level of change in the continuous endpoint that is biologically significant, the defined level of change is used as a BMR.
- B) A continuous data is expected to show various distributions, therefore, in the absence of biological significance in the level of change, select the BMR for each dose-response dataset in collaboration with experts.
- C) When there is a scientific basis to establish a cutoff value of the endpoint, a hybrid³ approach may be applied. After presuming a distribution of the data, specify the proportion of individuals who are expected to show higher/lower responses than the cutoff value in the control group. Then, a specified increase in the proportion of individuals who would show higher/lower responses than the cutoff value is defined as the BMR. In the Hybrid approach, calculate the dose corresponding to this defined BMR as the BMD.
- D) When there is a scientific basis to establish a cutoff value of the endpoint and individual data are available, continuous data can be dichotomized based on the cutoff value to select the BMR. Although it should be noted that this approach results in a loss of information, in some cases it is desirable to calculate BMD with this defined BMR.

3. Dose-response modeling for BMD calculation and determining POD

(1) Dose-response modeling (model fitting)

- A) All datasets that meet the conditions defined in 1. (2), above, should be considered for modeling to ensure that no endpoints with the potential to have the sensitive effects are excluded from the assessment.
- B) Fit a model to all dose-response data that describes the dataset. Dropping data on specific dose group(s) such as the highest dose group should not be conducted unless there is a biological basis.

³K. S. Crump, Calculation of Benchmark Doses from Continuous Data. Risk Analysis, 1995. 5: 79-89U.S. EPA, Benchmark Dose Technical Guidance. 2012.

- C) Ideally, the dose-response relationship for a given chemical and endpoint would be described by a biologically based single mathematical model that describes toxicokinetics and toxicodynamics processes related to the chemical.

When such a model that describes an essential mechanism of action (hereinafter referred to as “biologically based model”) is available, a priori selection of the model is recommended for modeling.

- D) In the absence of a biologically based model, use a set of models implemented in BMD software or on-line tools (hereinafter referred to as “software”) for modeling.
- E) Use the software with well-documented experience and theoretical background that allows BMD calculation judged reasonable by experts.
- F) If the model averaging approach⁴ is available in the software, also use the approach in the modeling process. All models in which the parameter estimates were obtained (converged) should be used for model averaging.
- G) When model specific restriction can be activated on model parameters, use both a model with and without restriction(s) imposed on the parameter(s) for the modeling based on the assumption that two models are distinct and they produce different results.

(2) Evaluating the results of the dose-response modeling and BMD calculation

For each dataset, the result from fitting each of the models and model averaging shall be evaluated as follows.

A) Model averaging is used

Individual dose-response curves derived from fitted models used in model averaging is evaluated based on how well the model describes the dose-response relationship (e.g. assessing goodness-of-fit). Model averaging is adopted if the evaluation result is judged appropriate by experts.

Further, the model used for model averaging that does not provide an adequate description of the data (i.e. the resulting curve does not adequately fit the dose-response data, not supported by visual examination or goodness-of-fit), may be rejected. In such case, remaining models that have met the criteria for adequacy may be used, while models with lack of fit are excluded.

⁴The average response is calculated by taking the weighted average from the fitted models using weights (i.e. such as AIC) with higher weights for models that fit the data better. Then the average model is derived from the weighted average response, while the BMD and its confidence intervals are calculated for the average model.

B) Model averaging is judged unsuitable to provide adequate or reliable results or model averaging is not used

All the fitted models are evaluated as follows.

- a. Reject the resulting curve that does not provide an adequate description of the data, not supported by visual examination or goodness-of-fit statistic under expert judgement.
Use a value of 0.1 to compute the critical value for goodness-of-fit. If there is a priori reason to use a specific model more conventional, suitable values may be used.
- b. All the fitted models are evaluated based on the following criteria from (a) to (d) based on expert judgement.
 - (a) The resulting curve is biologically plausible.
 - (b) The value of its AIC is within 3 units of the lowest AIC among all the fitted models.
 - (c) BMD estimates and its confidence intervals are sufficiently close with those of the remaining models.
 - (d) BMD estimates and the lower bounds of the confidence intervals are not significantly lower than the lowest dose observed.
- c. Select all the dose-response curves obtained from a model that have met the criteria described in the above b. When no model fulfills the criteria, judge whether it is appropriate to apply the BMD approach to the dataset under expert judgement.

(3) Determination of POD

A single or multiple independent dose-response curves are obtained for a specific dataset from (2).

Select dose-response curves by identifying endpoints that may be relevance to human health considering the relevance of endpoints that supports human extrapolation, characteristics of the data and experimental design, as well as BMD and its lower confidence limit (BMDL) in collaboration with experts. The lower bound of 90% confidence interval of the BMD (BMDL) calculated from the selected curve will be used as a POD.

4. Reporting of the BMD analysis

In reporting a BMD analysis for a target substance, the following information should be documented to allow deliberation and assessment at the relevant Expert Committee.

- (1) The software used, including the version number.
- (2) Information on each dataset to which BMD analysis is applied.
 - A) The study design employed such as target animal species, endpoint, and route/duration of administration.

- B) When open-access datasets are used, provide author(s) name, journal title, year of publication, and relevant information.
 - C) Information on dose-response data
 - a. Dichotomous (quantal) data: the total number of animals and the number of animals showing response for each dose level.
 - b. Ordinal categorical data: total number of animals, number of animals showing response and degree (grade) of response in each individual for each dose level.
When ordinal categorical data is reduced to quantal data, provide details of and rationale for the procedure employed.
 - c. Continuous data: number of animals, central estimate (mean or median value) and a measure of response variability (standard deviation (SD) or interquartile range) for each dose level.
 - D) When there is any variable considered as a covariate, provide the information.
 - E) When datasets are combined, the following should be provided: dataset information on C) and D), experimental design such as measurement of each dataset prior to combining the dataset, and justification for combining the datasets.
- (3) Selection of BMR and rationale for its selection
- (4) Result of dose-response modeling and BMD calculation to each dataset
- A) Plot of fitted-dose-response curve including the dose-response curve derived from model averaging and unconstrained/constrained curves.
 - B) Information on each fitted model(s) including BMD with its 90% confidence intervals and model fit indices such as AICs.
 - C) Information on the statistical method used for the calculation of the confidence limit for the BMD (likelihood profile, bootstrapping methods and others).
 - D) When model averaging is used, provide weights used for each dataset and the weighting estimate for each model.
- (5) Decision-making process for evaluating the fitted model for each dataset
- (6) POD determined, the rationale for selection of the endpoint and dataset to derive the POD

IV. Re-evaluation

This guideline shall be reviewed when deemed necessary, referring to globally accepted risk assessment methods for the use of the BMD approach and the up-to-date use of the BMD approach in risk assessment.